This is a working overview of thymosin beta-4, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-08-15. Anything still debated is marked as such rather than presented as settled.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈889 Da for the 7-residue fragment | Full-length thymosin beta-4 is ≈4.9 kDa; catalogs differ |
| Appearance | White to off-white powder | Hygroscopic; weight shifts with residual moisture |
| Solubility class | Freely soluble in water | Also dissolves in aqueous buffers; poorly soluble in nonpolar solvents |
| Typical storage temperature | −20 °C, desiccated, protected from light | Once rehydrated, short-term holding at 2-8 °C |
| Typical analytical method | Reversed-phase HPLC with mass spectrometry | Purity by UV absorbance; identity by ESI-MS or MALDI-TOF |
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
=== Special populations === In children and adolescents, fluoxetine is the antidepressant of choice due to tentative evidence favoring efficacy and tolerability. Evidence supporting an increased risk of major fetal malformations resulting from fluoxetine exposure is limited, although the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom has warned prescribers and patients of the potential for fluoxetine exposure in the first trimester (during organogenesis, formation of the fetal organs) to cause a slight increase in the risk of congenital cardiac malformations in the newborn. Furthermore, an association between fluoxetine use during the first trimester and an increased risk of minor fetal malformations was observed in one study. However, a systematic review and meta-analysis of 21 studies—published in the Journal of Obstetrics and Gynaecology Canada—concluded, "the apparent increased risk of fetal cardiac malformations associated with maternal use of fluoxetine has recently been shown also in depressed women who deferred SSRI therapy in pregnancy, and therefore most probably reflects an ascertainment bias. Overall, women who are treated with fluoxetine during the first trimester of pregnancy do not appear to have an increased risk of major fetal malformations." Per the US Food and Drug Administration (FDA), infants exposed to SSRIs in late pregnancy may have an increased risk for persistent pulmonary hypertension of the newborn.
Following the House passage of OBBBA, the bill moved to the Senate for consideration. The Republican-led Senate amended the bill. Fiscally conservative Republican Senators (nicknamed "deficit hawks") such as Ron Johnson of Wisconsin, Rick Scott of Florida, Mike Lee of Utah, and Rand Paul of Kentucky, pushed for deeper spending cuts. Moderate Republicans such as Susan Collins of Maine, Lisa Murkowski of Alaska, and Jerry Moran of Kansas, along with populist Josh Hawley of Missouri, expressed concerns about Medicaid cuts. Other moderates such as John Curtis of Utah and Thom Tillis of North Carolina, along with Murkowski and Moran, expressed concerns over the end of green energy tax credits. Defense hawks such as Mike Rounds of South Dakota were opposed to spectrum auction provisions in the bill. Democrats in the Senate sought to use the Byrd Rule, which prevents reconciliation from being used to pass "extraneous" measures in bills which increase federal spending in the Senate, in order to strip certain provisions from the bill. Democrats argued that the extension of Trump's 2017 tax cuts, a proposed 10-year ban on state level AI regulations, language that limits the power of federal court to enforce contempt of court citations, a provision to end a tax on the manufacturing of gun silencers, a provision to defund Planned Parenthood, a provision banning Medicaid from funding gender-affirming care for people of all ages and a provision to streamline permits for fossil fuel projects, violated the Byrd Rule.
TikTok tends to appeal to younger users, as 41% of its users are between the ages of 16 and 24. As of 2021, these individuals are considered Generation Z. TikTok's geographical use in 2019 has shown that 43% of new users were from India before the social platform was banned in the country. But adults have also seen growth on TikTok. The share of US adults who regularly get news from TikTok hit 5% in 2025. By July 2023, TikTok has become the primary news source for British teenagers on social media, with 28% of 12 to 15-year-olds relying on the platform, while traditional sources like BBC One/Two are more trusted at 82%, according to a report by UK regulator Ofcom. As of the first quarter of 2022, there were over 100 million monthly active users in the United States and 23 million in the UK. The average user, daily, was spending 1 hour and 25 minutes on the app and opening TikTok 17 times. Out of TikTok's top 100 male creators, a 2022 analysis reported 67% were white, with 54% having near-perfect facial symmetry.
60 amino acids in the extracellular N-terminal domain three transmembrane helices (TM1, 2, and 3) an intracellular loop of 46 amino acids connecting TM1 and TM2 a short intracellular C-terminal domain of 15 amino acids. The homotrimeric assembly is conserved across species, from plants, yeast to mammals.
Sources: en.wikipedia.org
2 glutathione + lipid–hydroperoxide → glutathione disulfide + lipid–alcohol + H2O This reaction occurs at the selenocysteine within the catalytic center of GPX4. During the catalytic cycle of GPX4, the active selenol (-SeH) is oxidized by peroxides to selenenic acid (-SeOH), which is then reduced with glutathione (GSH) to an intermediate selenodisulfide (-Se-SG). GPX4 is eventually reactivated by a second glutathione molecule, releasing glutathione disulfide (GS-SG).
==== MeSH E05.318.760 – epidemiologic study characteristics ==== MeSH E05.318.760.500 – epidemiologic studies MeSH E05.318.760.500.500 – case-control studies MeSH E05.318.760.500.500.500 – retrospective studies MeSH E05.318.760.500.750 – cohort studies MeSH E05.318.760.500.750.500 – longitudinal studies MeSH E05.318.760.500.750.500.350 – follow-up studies MeSH E05.318.760.500.750.500.650 – prospective studies MeSH E05.318.760.500.875 – cross-sectional studies MeSH E05.318.760.500.950 – seroepidemiologic studies MeSH E05.318.760.500.950.375 – hiv seroprevalence MeSH E05.318.760.535 – clinical trials MeSH E05.318.760.535.200 – clinical trials, phase i MeSH E05.318.760.535.210 – clinical trials, phase ii MeSH E05.318.760.535.220 – clinical trials, phase iii MeSH E05.318.760.535.230 – clinical trials, phase iv MeSH E05.318.760.535.365 – controlled clinical trials MeSH E05.318.760.535.365.500 – randomized controlled trials MeSH E05.318.760.535.500 – multicenter studies MeSH E05.318.760.550 – feasibility studies MeSH E05.318.760.565 – intervention studies MeSH E05.318.760.750 – pilot projects MeSH E05.318.760.875 – sampling studies MeSH E05.318.760.900 – twin studies
=== Acquired resistance === Evolution of microbial resistance to vancomycin is a growing problem, especially in healthcare facilities such as hospitals. While newer alternatives to vancomycin exist, such as linezolid (2000) and daptomycin (2003), the widespread use of vancomycin makes resistance to it a significant worry, especially for individual patients if resistant infections are not quickly identified and the patient continues an ineffective treatment. Vancomycin-resistant Enterococcus emerged in 1986. Vancomycin resistance evolved in more common pathogenic organisms during the 1990s and 2000s, including vancomycin-intermediate S. aureus (VISA) and vancomycin-resistant S. aureus (VRSA). Agricultural use of avoparcin, another similar glycopeptide antibiotic, may have contributed to the evolution of vancomycin-resistant organisms. One mechanism of resistance to vancomycin involves the alteration to the terminal amino acid residues of the NAM/NAG-peptide subunits, under normal conditions, D-alanyl-D-alanine, to which vancomycin binds. The D-alanyl-D-lactate variation results in the loss of one hydrogen-bonding interaction (4, as opposed to 5 for D-alanyl-D-alanine) possible between vancomycin and the peptide. This loss of just one point of interaction results in a 1000-fold decrease in affinity. The D-alanyl-D-serine variation causes a six-fold loss of affinity between vancomycin and the peptide, likely due to steric hindrance. In enterococci, this modification appears to be due to the expression of an enzyme that alters the terminal residue.
Sources: en.wikipedia.org
=== Metabolome atlas of the aging mouse brain === In 2021, the first brain metabolome atlas of the mouse brain – and of an animal (a mammal) across different life stages – was released online. The data differentiates by brain regions and the metabolic changes could be "mapped to existing gene and protein brain atlases".
It's a little sarcastic, but it's pretty much about dealing with your mortality and life. Everybody's going to die someday. Instead of being afraid of it, that's the way it is: so enjoy the time you've got. Live as much as you can, have as much fun as possible. Face your fear and live. I had family members die at a fairly early age; so I've always had kind of a phobia about it. Death freaks me out. I think it freaks a lot of people out. It's the end of life, depending on your views. It's a pretty scary thing. "Them Bones" is trying to put that thought to rest. Use what you have left, and use it well." Cantrell was inspired to write "Dam That River" after a fight he had with Sean Kinney, in which Kinney broke a coffee table over his head. The lyrics to "Rain When I Die" were written by Cantrell and Staley about their respective girlfriends. "Sickman" came together after Staley asked Cantrell to "write him the sickest tune, the sickest, darkest, most fucked up and heaviest thing [Cantrell] could write." "Rooster" was written by Cantrell for his father, Jerry Cantrell Sr., who served in the Vietnam War and his childhood nickname was "Rooster". Cantrell described the song as "the start of the healing process between my Dad and I from all that damage that Vietnam caused." Discussing the title track "Dirt", Cantrell stated that "the words Layne put to it were so heavy, I've never given him something and not thought it was gonna be the most bad-assed thing I was going to hear." Staley said he wrote the song "to a certain person who basically buried my ass".
== Recognition == In November 2013, Schrödinger, in collaboration with Cycle Computing and the University of Southern California, set a record for the world's largest and fastest cloud computing run by using 156,000 cores on Amazon Web Services to screen over 205,000 molecules for materials science research. That work was a follow-up to a 2012 collaboration which saw Cycle Computing creating a 50,000 core virtual supercomputer using Amazon and Schrödinger's infrastructure; at that time, it was used to analyze 2.1 million compounds in 3 hours.
Sources: en.wikipedia.org
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.
The name is a commercial label rather than a systematic chemical designation, so different vendors and papers attach it to different sequences. Some treat it as a fragment and others as the whole protein. Comparing two reports therefore requires checking what each one actually analyzed.
Typically it reflects the relative area of the main peak in a reversed-phase chromatogram at a given wavelength. It does not confirm the amino acid sequence, the counter-ion, or the amount of peptide by mass. Identity is normally established by a separate mass measurement.
Standard practice is a desiccated container at −20 °C, protected from light and kept sealed between uses. Letting the vial reach room temperature before opening reduces condensation on the powder. Repeated warming and cooling of the whole container is generally avoided.